SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board: 
Last Post: 3/24/2017 4:03:41 PM - Followers: 829 - Board type: Free - Posts Today: 107

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: [email protected]

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:48:03 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:42:25 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:27:37 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:19:06 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 02/27/2017 06:10:49 PM
#247416  Sticky Note HERE is WHAT long term investors need to UNDERSTAND!!! Couch 03/21/17 06:12:24 PM
#239443  Sticky Note Yes IMO first SequestOx FDA Commercial approval in lasers 01/17/17 11:02:44 PM
#236265  Sticky Note Elite Pharma: The company of firsts: namtae 12/14/16 12:32:00 PM
#234937  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 11/30/16 03:04:07 PM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#247786   No one has ever been harmed by original NASDAQ2020 03/24/17 04:03:40 PM
#247785   20 seconds before close SCHH 03/24/17 04:02:06 PM
#247784   How many OD'd already? namtae 03/24/17 03:57:11 PM
#247783   "Revenues were $2.3 million for the quarter and NASDAQ2020 03/24/17 03:51:53 PM
#247782   The global opioid market reached $33.924 billion in NASDAQ2020 03/24/17 03:47:07 PM
#247781   The Fed Tmax study almost half over. NASDAQ2020 03/24/17 03:43:40 PM
#247780   should not take long John_Langston 03/24/17 03:41:54 PM
#247779   You are showing your age! LOL. CMDawg 03/24/17 03:41:01 PM
#247778   After Priority Expedited Review. NASDAQ2020 03/24/17 03:40:24 PM
#247777   The bidding begins after SequestOx Approval John_Langston 03/24/17 03:35:40 PM
#247776   I totally agree with your characterization of the conix 03/24/17 03:32:33 PM
#247775   BP will out bid PuriCap NASDAQ2020 03/24/17 03:31:00 PM
#247774   so far no insiders have reported sales, big dr_lowenstein 03/24/17 03:30:43 PM
#247773   just went up a tic.... now down a Jimmy Joe 03/24/17 03:29:28 PM
#247772   WOW, i just looked away for a bit Jimmy Joe 03/24/17 03:28:39 PM
#247771   People take solace in the fact that Elite Jimmy Joe 03/24/17 03:26:01 PM
#247770   yeah but over a decade ago they looked dr_lowenstein 03/24/17 03:20:25 PM
#247769   that is hysterically funny. elite has been developing dr_lowenstein 03/24/17 03:11:00 PM
#247768   Your right, The Buyout will stop Elite in NASDAQ2020 03/24/17 03:06:37 PM
#247767   Gee the facts stand - the PPS was John_Langston 03/24/17 03:06:08 PM
#247766   Ask for Jenny John_Langston 03/24/17 03:02:32 PM
#247765   Any chance PuraCap buys us out after the John_Langston 03/24/17 03:00:59 PM
#247764   CEO If you're familiar with the valuation accretion NASDAQ2020 03/24/17 03:00:43 PM
#247763   That's the problem Elite'S pipeline may NEVER get stockboy 03/24/17 02:57:23 PM
#247762   Nasrat could drop Generic Embeda on us any time. NASDAQ2020 03/24/17 02:56:33 PM
#247761   Where can we watch for these UNDISCLOSED filings namtae 03/24/17 02:53:34 PM
#247760   Elite's Current Marketed Products and Pipeline is growing NASDAQ2020 03/24/17 02:49:07 PM
#247759   SequestOx™ will receive Oral, Nasal and IV ADF NASDAQ2020 03/24/17 02:46:54 PM
#247758   Elite will have 100% exclusivity in these NASDAQ2020 03/24/17 02:45:59 PM
#247757   WeeZuhl, On your somewhat recent post about the mrwrn2010 03/24/17 02:43:17 PM
#247756   WOW, i just looked away for a bit namtae 03/24/17 02:38:18 PM
#247755   Oh, dont you really mean play "make believe"!! namtae 03/24/17 02:37:22 PM
#247754   Purdue is a one trick pony whose trick Jimmy Joe 03/24/17 02:24:26 PM
#247752   Opioid abuse problem came up again today during Jimmy Joe 03/24/17 02:19:43 PM
#247751   Purdue no longer has any big money generating lasers 03/24/17 02:19:19 PM
#247750   Has PuraCap made a partnership with Elite? namtae 03/24/17 02:19:11 PM
#247749   Short story, Purdue determined that their Hot Melt Jimmy Joe 03/24/17 02:15:26 PM
#247748   Oh my, now Purdue is running out of dr_lowenstein 03/24/17 02:14:42 PM
#247747   Lol lol yeah since that stupid decision purdue dr_lowenstein 03/24/17 02:12:11 PM
#247746   It's like the the claim the TA isn't John_Langston 03/24/17 02:11:19 PM
#247745   91+% of new opiod RXs are for Immediate NASDAQ2020 03/24/17 02:10:03 PM
#247744   7 Pathways to DollarLand NASDAQ2020 03/24/17 02:07:39 PM
#247743   but dont forget Purdue said thanks but Jimmy Joe 03/24/17 02:07:30 PM
#247742   SEQUESTOX GREEN LIGHTED BY FDA IN DEC NASDAQ2020 03/24/17 02:06:55 PM
#247741   I guess then they'll just become a Carmel toofun 03/24/17 01:38:21 PM
#247740   Purdue has rapidly dwindling cash as they have lasers 03/24/17 01:36:39 PM
#247739   I've think that Purdue will sell their hot toofun 03/24/17 01:26:05 PM
#247738   LOL LOL how many pharma cases have they dr_lowenstein 03/24/17 01:23:32 PM
#247737   IP Litigation lawyers BakerHostetler are more than prepared lasers 03/24/17 01:21:19 PM
#247736   That would be correct Couch. As well $ELTP lasers 03/24/17 01:18:53 PM